Remdesivir may cut hospitalization risk for high-risk COVID outpatients

If you’re at high risk for severe COVID and trying to stay out of the hospital, this finding matters. A new Bayesian reanalysis of a randomized trial looked at outpatients with COVID-19 who were at high risk of severe disease. It found that remdesivir was linked to a much lower chance of COVID-related hospitalization or death. The analysis estimated the treatment cut that risk by about 87%, with a 95% credible interval suggesting the true benefit could range from a 53% to a 98% reduction. The data came from people treated as outpatients, but the original sample size and follow-up time weren’t reported. Safety data weren’t included in this reanalysis, so we don’t know about side effects here. Because this is a reanalysis of existing trial data, it supports the idea that remdesivir can help, but it’s not brand-new evidence on its own. The findings are strong within the model used, yet they still depend on the underlying trial.